+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 45Years - 75Years
All Genders
ID06948357

Phase II Study of BRIMOCHOL PF and CARBACHOL PF Eye Drops for Treating Presbyopia in Chinese Adults Aged 45 to 75

Led by Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. · Updated on 2025-04-29

119

Participants Needed

1

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of BRIMOCHOL PF and CARBACHOL PF eye drops in treating presbyopia in Chinese patients. This Phase II, multicenter, randomized, double-blind, placebo-controlled study involves 119 participants aged 45 to 75 years. The study uses a crossover design to compare these treatments with placebo and brimonidine eye drops, aiming to improve near and distance visual acuity. Participants will be randomly assigned to one of seven treatment sequences. Each participant will receive seven different treatments over separate visits, including single and twice dosing of BRIMOCHOL PF, CARBACHOL PF, brimonidine, and placebo eye drops. The treatment periods last one day each, with at least three days between treatments. The study includes a screening period followed by a treatment period with a total of eight visits over 32 to 45 days. During the study, participants will undergo vision tests to measure changes in monocular and binocular corrected near and distance visual acuity at various time points after eye drop administration. Researchers will also assess changes in pupil diameter. The study monitors safety and efficacy through scheduled visits, with the primary outcome focusing on visual acuity changes up to eight hours after treatment.

CONDITIONS

Brief Title

Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients

Research Team

P

Peiqiu Gu

X

Xiaochen Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here